DNAprint Genomics (DNAG)

[Theo]

NEWS:
http://biz.yahoo.com/iw/051117/0101554.html

DNAPrint genomics CEO Richard Gabriel Featured in Interview in Wall Street Transcript's Biotechnology Issue
Thursday November 17, 7:00 am ET

SARASOTA, FL--(MARKET WIRE)--Nov 17, 2005 -- DNAPrint(TM) genomics, Inc. (OTC BB:DNAG.OB - News) today announced that The Wall Street Transcript has published a biotechnology issue which features a comprehensive interview with Richard Gabriel, the Company's President and Chief Executive Officer.

During the interview Mr. Gabriel traces how DNAPrint genomics has evolved into a company focused on three areas: pharmacogenomics and the development of personalized test/drug combinations called theranostics; genealogy, which is basically a consumer ancestry product, and forensics for law enforcement. "Pharmacogenomics is the Company's biggest market opportunity, and we've focused on developing pharmaceutical applications for our products and services," he stated.

The interview is available the Company's website at www.dnaprint.com and can be accessed by subscribers on the Transcript's Web site (www.twst.com).

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673.

About DNAPrint

DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


Contact:

Company Contact:
Richard Gabriel
President and CEO
941-366-3400

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848


Source: DNAPrint Genomics, Inc.